Furthermore, meloxicam has been shown to inhibit proliferation and migration of hepatoma cells by targeting COX-2/PGE2 to regulate activation of the β-catenin signaling pathway (Li et al., 2016). This evidence concerns the gene PTGS2 and hepatocellular carcinoma.